Falling sales, rising orders
4basebio's latest interim figures contain an apparent contradiction: Revenue fell sharply in the first half of 2026, yet orders, client numbers and the company's qualified sales pipeline all grew. The question is why sales dropped while commercial activity increased, and what the gap means for a Business still spending heavily ahead of revenue.
What the company makes
4basebio (LSE:4BB) is an AIM-quoted biotechnology company that produces synthetic DNA for genetic medicines. Its proprietary opDNA product is made enzymatically rather than through traditional bacterial fermentation, and is used as starting material for mRNA vaccines and therapies, cell therapies and viral vectors. The company supplies both laboratory-grade and clinical-grade material, and its Facility has achieved GMP certification from the MHRA, the UK medicines regulator, allowing it to support customers' clinical programmes.
The half-year report and a new partnership
On 28 September 2026, 4basebio published results for the six months to 30 June 2026. Revenue was only about £0.3 million, compared with £1.2 million a year earlier, which the company attributed to project delays. The loss for the period widened to £8.9 million from £7.8 million. Cash stood at £14.1 million, down from £17.8 million at 31 December 2025, after a €7 million Loan drawdown, with non-current financial liabilities to lender 2Invest AG of £22.3 million. The company said its cash runway extends into late 2027.
The commercial indicators were more encouraging. Sales orders rose 210% to £1.2 million, the qualified pipeline reached £63 million, a six-fold increase since the third quarter of 2025, and the client base totalled 134, with 28 new programmes signed in 2026. Chief executive Dr Amy Walker said the half had brought good commercial momentum, positioning the company well for future growth.
The same morning, the company announced a Partnership with TriLink BioTechnologies. 4basebio will Supply clinical-grade opDNA for a pharmaceutical company's Phase I cell therapy programme, while TriLink manufactures the mRNA drug substance using its CleanCap capping technology. Commercial terms were not disclosed. Chief commercial officer Christine Wolosin described the collaboration as "a testament to the quality and consistency of our opDNA platform". In August, it also announced a collaboration with Genezen, a viral vector contract manufacturer.
Reading the numbers
The timing gap between orders and recognised revenue appears central. Orders and pipeline measure work that may be delivered later, while revenue is recognised when products are supplied. The company itself expects full-year 2026 revenue to be lower than in 2025 because of the slow first half, but forecasts significant growth in the second half and in 2027. It also said its operating cost base had stabilised and it expects reduced operating cash outflows from the second half onwards. Capital Expenditure of £1.1 million in the half went mainly on fitting out its Saxon Way facility, adding production capacity.
Risks to watch
A qualified pipeline is not contracted revenue, and project delays have already affected one reporting period. The business relies on borrowings that now exceed its cash balance, so continued losses would increase pressure to raise funds or refinance before the runway ends. Many customers are early-stage developers whose programmes can be paused or cancelled. Competition from established plasmid DNA suppliers, which have long-standing relationships with drug developers, is a further consideration. Investors may also watch for evidence that the MHRA GMP certification is converting into repeat clinical supply contracts, and for any change to the 2Invest facility terms.
Conclusion
4basebio's half-year revenue fell because customer projects were delayed, not, according to the company, because Demand weakened: orders, clients and pipeline all increased, and partnerships with TriLink and Genezen broaden its reach. Whether this translates into the second-half revenue growth management expects will determine how comfortably the company's cash lasts into late 2027.

_11_18_2026_09_42_19_750506.jpg)
_11_18_2026_09_43_10_583784.jpg)



Please wait processing your request...